Contraceptives

This article discusses how the marketing of controversial drugs in developing countries demonstrates the power and priorities of the pharmaceutical industry. Example highlighted: Estrogen-Progesterone combination drugs. 

A set of eight advocacy briefs on the benefits of long-acting and permanent methods (LAPMs) of contraception and the rationale for introducing or revitalizing them within national reproductive health and family planning programs. Intends to inform policy-makers, program managers, and donors committed to evidence-based policies and programs that respond to people's changing reproductive needs. Seeks also to provide diverse stakeholders with ideas on how to improve and expand LAPM provision within their communities.

Examines the ongoing story of Depo Provera, including: its regulatory history; how it has been and continues to be used, and; what is known about its safety profile.